DexCom, Inc.

- No explicit mention of current or planned new fundraising through debt or equity in the provided transcript. - The company highlights a strong cash position with approximately $2.4 billion of cash and equivalents as of Q1 2026, up $400 million from year-end 2025. - They have recently paid down convertible debt and completed $500 million in share buybacks, indicating active capital allocation but not new fundraising. - Management emphasizes flexibility with the existing cash balance for multiple uses, including tuck-in M&A and potential capital markets actions. - Detailed capital allocation plans, including possible future funding approaches, are expected to be discussed at the upcoming Investor Day. - Overall, the commentary suggests no immediate plans to raise new debt or equity but indicates openness to strategic financial actions if opportunities arise.

- The company is continuing to invest in ramping up its manufacturing facility in Ireland, with expected increased spending in Q2 and Q3 as the facility becomes fully operational. - Investments in R&D are set to increase after a flat year-over-year Q1, including continued investment in Ireland. - The strategic focus on tuck-in M&A opportunities remains, particularly for geographic expansion or acquiring new capabilities. - Maintaining a strong cash balance provides flexibility for future capital markets activities and share buybacks, with further capital allocation details to be discussed at the upcoming Investor Day. - Product launches such as Smart Basal are part of long-term strategic investments to improve patient outcomes and utilization.

- 2026 revenue guidance reaffirmed at $5.16 billion to $5.25 billion, representing 11% to 13% organic growth (Page 4). - Growth expected to be fairly evenly split between U.S. and international markets; U.S. comps tougher in early 2026 but easier later, international the reverse (Page 9). - Continued expansion through new product launches (e.g., G7 15 Day, Stelo internationally in 2026) and broadening insurance coverage (Page 3, 9). - Record global new patient starts in Q1 2026; U.S. new patient starts close to record (Page 6). - Long runway for U.S. CGM penetration as only ~30% of covered lives currently use CGM (Page 4). - Focus on retention, utilization and customer experience improvements to drive lifetime patient value and revenue growth (Pages 9,15). - Additional coverage gains expected (e.g., CMS Medicare), expanding access to new patient populations and supporting durable long-term growth (Pages 4, 6, 15).

- Full-year revenue guidance reaffirmed at $5.16 billion to $5.25 billion, representing 11% to 13% growth. - Non-GAAP gross profit margin guidance maintained at 63% to 64%. - Increased non-GAAP operating profit margin guidance to 23% to 23.5% (raised midpoint by 75 basis points). - Adjusted EBITDA margin guidance raised to 31% to 31.5%. - Q1 net income was $216.3 million, up 75% year-over-year, with EPS of $0.56. - Operating expenses expected to rise, especially R&D investment due to Ireland manufacturing ramp-up; R&D flat in Q1 but set to increase. - Guidance reflects conservative gross margin due to geopolitical factors, with strong cost controls supporting margin improvements. - Further details on capital allocation and growth strategies expected at the upcoming Investor Day.

The provided transcript excerpts from the PDF "8360533-27390.pdf" do not explicitly mention the current or expected orderbook or pending orders. However, relevant insights related to demand and business momentum include: - The company reported record global new patient starts in Q1, indicating strong demand. - Momentum is building behind new products like the 15 Day and Stelo systems. - Multiple coverage wins, including Prime Therapeutics and CMS coverage expansion, are expected to unlock additional demand and revenue growth. - International business is ramping up, including manufacturing facility expansions in Ireland. - The company anticipates continued double-digit organic revenue growth (11%-13%) split evenly between U.S. and international markets. - Leverage in operating expenses and strong gross margin performance support confidence in growth. No specific quantitative figures on current or pending orders or order book size are disclosed.